Quick Answer
Dare Bioscience, Inc. reported Diluted EPS of $1.20 per share (loss) for fiscal year 2025.
Dare Bioscience, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.20 | -150.0% |
| 2024 | -$0.48 | +88.4% |
| 2023 | -$4.15 | -1021.6% |
| 2022 | -$0.37 | +41.3% |
| 2021 | -$0.63 | +30.8% |
| 2020 | -$0.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.28 | +49.1% | +37.8% |
| June 30, 2025 | -$0.45 | -129.6% | +10.0% |
| March 31, 2025 | -$0.50 | +38.3% | +9.1% |
| September 30, 2024 | -$0.55 | +49.5% | -136.2% |
| June 30, 2024 | $1.52 | +224.6% | +287.7% |
| March 31, 2024 | -$0.81 | -800.0% | +25.7% |
| September 30, 2023 | -$1.09 | -1262.5% | +10.7% |
| June 30, 2023 | -$1.22 | — | -1255.6% |
- Dare Bioscience, Inc. showed a decrease of -150.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Dare Bioscience, Inc.’s diluted eps has declined by 31.9% (from $0.91 per share (loss) to $1.20 per share (loss)).
- The most recent figure is from Dare Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: